Drug Profile

Research programme: anti-fungals - Elitra

Alternative Names: Anti-fungals research programme - Elitra

Latest Information Update: 19 Apr 2007

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Concordia University; Elitra Canada (CEASED); McGill University; Natural Sciences and Engineering Research Council of Canada; University of Toronto
Class
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

19 Apr 2007 Discontinued - Preclinical for Mycoses in Canada (unspecified route)
02 Jul 2002 This programme is still in active development
22 Dec 2000 Mycota Biosciences has been acquired by Elitra Pharmaceuticals and renamed Elitra Canada

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com